ORIC Pharmaceuticals, Inc.
NASDAQ:ORICBiotechnology
-$0.07 today
- Market cap
- $795.08M
- Beta
- 1.06
- P/E (TTM)
- -6.7
- EPS (TTM)
- -$1.28
Volume 1.39M
Average 1.91M
ORIC Net Income
Bottom-line profit, the starting point for calculating cash from operations.
ORIC Pharmaceuticals, Inc.NASDAQ: ORIC
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income growth accelerates
Q1 FY2026 net income of $35.77M (cash outflow) rose 19.1% year over year, ahead of the +1.8% change in trailing-twelve-month net income. Sequentially, it rose 17.2% from the prior quarter. Over 3 fiscal years it compounded at +13.3% a year.
Context
- Net income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 11 analysts of -$128.9M (-0.4%) for the fiscal year ending Dec 2026, a slowdown from the +1.3% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$35.77M+17.2% QoQ
- Last fiscal yearDec 2025
- -$129.47M+1.3% YoY
- LTMMar 2026
- -$135.21M+1.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +19.1% | +4.3% | -14.8 pp |
| 1 year | +1.3% | -0.4% | -1.7 pp |
| 3-year CAGR | +13.3% | +2.8% | -10.4 pp |
| 5-year CAGR | -14.9% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (129.47M) USD
- Year-over-year change
- -1.3%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (129.47M) | -1.3% |
| FY2024 | 2024-12-31 | (127.85M) | -27.0% |
| FY2023 | 2023-12-31 | (100.7M) | -13.0% |
| FY2022 | 2022-12-31 | (89.12M) | -13.2% |
| FY2021 | 2021-12-31 | (78.72M) | — |
Net Income vs competitors
How ORIC compares with its peers on the latest reported figures
- ORIC's LTM Mar 2026 net income of $135.21M is the 4th largest of the 11 companies compared; the peer median is $113.98M.
- Its year-over-year change of +1.8% is the 10th highest of 11, against a peer median of +28.2%.
- Over three fiscal years its annual growth of +13.3% compares with a peer median of +24.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $243.25M | -26.6% | +24.1% | 112.0% | |
| LTM Mar 2026 | $193.96M | +30.3% | +41.6% | 391.2% | |
| LTM Mar 2026 | $145.24M | +14.0% | +65.2% | — | |
| LTM Mar 2026 | $135.21M | +1.8% | +13.3% | — | |
| LTM Mar 2026 | $131.11M | +36.0% | +29.4% | — | |
| LTM Mar 2026 | $114.48M | +47.3% | +21.7% | 529.7% | |
| LTM Sep 2026 | $113.48M | +16.7% | +40.2% | — | |
| LTM Jun 2026 | $112.24M | +155.3% | +25.2% | 66.1% | |
| LTM Mar 2026 | $70.36M | +26.1% | -14.6% | 44.8% | |
| LTM Mar 2026 | $44.17M | +6.7% | -28.2% | — | |
| LTM Mar 2026 | $29.59M | +46.8% | +11.5% | — | |
| Peer median (excluding ORIC) | $113.98M | +28.2% | +24.7% | 112.0% | |
Competitors are the stored peer set for ORIC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (78.72M) | (89.12M) | (100.7M) | (127.85M) | (129.47M) |
| Depreciation & Amortization | 897K | 966K | 1.03M | 1.11M | 1.22M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 12.85M | 14.46M | 15.23M | 20.21M | 0 |
| Change in Working Capital | 4.07M | (445K) | 4.9M | 1.97M | (5.46M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 2.93M | (1.48M) | 0 | 1.83M | (7.25M) |
| Other Working Capital | 1.14M | 1.03M | 4.9M | 143K | 1.79M |
| Other Non-Cash Items | 1.35M | (1M) | (6.15M) | (8.1M) | 20.34M |
| Operating Cash Flow | (59.54M) | (75.14M) | (85.69M) | (112.66M) | (113.37M) |
| Capital Expenditures | (939K) | (2.08M) | (849K) | (1.19M) | (712K) |
| Acquisitions (Net) | 1.38M | 2.08M | 0 | 0 | 0 |
| Purchases of Investments | (69.63M) | (238.12M) | (239.24M) | (251.92M) | (399.82M) |
| Sales of Investments | 229M | 130.95M | 196.69M | 275.25M | 252.5M |
| Other Investing Activities | (1.38M) | (2.08M) | 0 | 0 | 0 |
| Investing Cash Flow | 158.44M | (109.25M) | (43.4M) | 22.14M | (148.03M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 50M | 25M | 85M | 125M | 247.66M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (866K) | 225K | 658K | 1.55M | 0 |
| Financing Cash Flow | 49.13M | 25.23M | 85.66M | 126.55M | 247.66M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 148.03M | (159.17M) | (43.43M) | 36.02M | (13.74M) |
| Free Cash Flow | (60.48M) | (77.22M) | (86.54M) | (113.85M) | (114.08M) |
ORIC Pharmaceuticals, Inc.
NASDAQ:ORIC
Intrinsic Alpha fair value
Locked
Current Price
$7.65
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.